- Home
- CHW vs KMDA Comparison
CHW vs KMDA Comparison
Compare CHW & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHW
- KMDA
- Stock Information
- Founded
- CHW 2007
- KMDA 1990
- Country
- CHW United States
- KMDA Israel
- Employees
- CHW N/A
- KMDA N/A
- Industry
- CHW Investment Managers
- KMDA Biotechnology: Pharmaceutical Preparations
- Sector
- CHW Finance
- KMDA Health Care
- Exchange
- CHW Nasdaq
- KMDA Nasdaq
- Market Cap
- CHW 420.9M
- KMDA 399.7M
- IPO Year
- CHW N/A
- KMDA N/A
- Fundamental
- Price
- CHW $6.97
- KMDA $7.86
- Analyst Decision
- CHW
- KMDA Strong Buy
- Analyst Count
- CHW 0
- KMDA 3
- Target Price
- CHW N/A
- KMDA $14.67
- AVG Volume (30 Days)
- CHW 195.2K
- KMDA 82.3K
- Earning Date
- CHW 01-01-0001
- KMDA 08-13-2025
- Dividend Yield
- CHW 9.27%
- KMDA 2.55%
- EPS Growth
- CHW N/A
- KMDA 31.21
- EPS
- CHW N/A
- KMDA 0.28
- Revenue
- CHW N/A
- KMDA $167,235,000.00
- Revenue This Year
- CHW N/A
- KMDA $14.51
- Revenue Next Year
- CHW N/A
- KMDA $9.31
- P/E Ratio
- CHW N/A
- KMDA $27.91
- Revenue Growth
- CHW N/A
- KMDA 11.83
- 52 Week Low
- CHW $5.07
- KMDA $4.83
- 52 Week High
- CHW $6.54
- KMDA $9.16
- Technical
- Relative Strength Index (RSI)
- CHW 64.35
- KMDA 74.32
- Support Level
- CHW $6.75
- KMDA $7.13
- Resistance Level
- CHW $6.91
- KMDA $8.20
- Average True Range (ATR)
- CHW 0.07
- KMDA 0.20
- MACD
- CHW -0.01
- KMDA 0.09
- Stochastic Oscillator
- CHW 95.65
- KMDA 77.48
About CHW Calamos Global Dynamic Income Fund
Calamos Global Dynamic Income Fund operates as a closed-end management investment company. The company's investment objective is to generate a high level of current income with the objective of capital appreciation. It dynamically allocates its investment among equities, convertible bonds, fixed-income securities and alternative investments.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.